Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1987 Aug;25(8):1576–1578. doi: 10.1128/jcm.25.8.1576-1578.1987

Effect of inoculum size on results of macrotube broth dilution susceptibility tests with Branhamella catarrhalis.

G V Doern, T Tubert
PMCID: PMC269279  PMID: 3624453

Abstract

The effect of inoculum size on the results of macrotube broth dilution MICs was assessed with 15 strains of Branhamella catarrhalis versus 22 antimicrobial agents. The study isolates included five beta-lactamase-negative strains, five strains that produced beta-lactamase and for which ampicillin MICs were high, and five beta-lactamase-producing strains for which ampicillin MICs were low. An inoculum effect was observed only with strains in the last group when tested versus the following antimicrobial agents: penicillin G, ampicillin, cephalothin, cefamandole, cefuroxime, and cefaclor.

Full text

PDF
1576

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alvarez S., Jones M., Holtsclaw-Berk S., Guarderas J., Berk S. L. In vitro susceptibilities and beta-lactamase production of 53 clinical isolates of Branhamella catarrhalis. Antimicrob Agents Chemother. 1985 Apr;27(4):646–647. doi: 10.1128/aac.27.4.646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Branhamella catarrhalis. Lancet. 1982 May 29;1(8283):1244–1245. [PubMed] [Google Scholar]
  3. Davies B. I., Maesen F. P. Epidemiological and bacteriological findings on Branhamella catarrhalis respiratory infections in The Netherlands. Drugs. 1986;31 (Suppl 3):28–33. doi: 10.2165/00003495-198600313-00008. [DOI] [PubMed] [Google Scholar]
  4. Doern G. V. Branhamella catarrhalis--an emerging human pathogen. Diagn Microbiol Infect Dis. 1986 Mar;4(3):191–201. doi: 10.1016/0732-8893(86)90098-2. [DOI] [PubMed] [Google Scholar]
  5. Doern G. V., Miller M. J., Winn R. E. Branhamella (Neisseria) catarrhalis systemic disease in humans. Case reports and review of the literature. Arch Intern Med. 1981 Nov;141(12):1690–1692. [PubMed] [Google Scholar]
  6. Doern G. V., Tubert T. A. Detection of beta-lactamase activity among clinical isolates of Branhamella catarrhalis with six different beta-lactamase assays. J Clin Microbiol. 1987 Aug;25(8):1380–1383. doi: 10.1128/jcm.25.8.1380-1383.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Johnson M. A., Drew W. L., Roberts M. Branhamella (Neisseria) catarrhalis--a lower respiratory tract pathogen? J Clin Microbiol. 1981 Jun;13(6):1066–1069. doi: 10.1128/jcm.13.6.1066-1069.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Labia R., Barthelemy M., Le Bouguennec C. B., Buu Hoi-Dang Van A. Classification of beta-lactamases from Branhamella catarrhalis in relation to penicillinases produced by other bacterial species. Drugs. 1986;31 (Suppl 3):40–47. doi: 10.2165/00003495-198600313-00011. [DOI] [PubMed] [Google Scholar]
  9. Louie M. H., Gabay E. L., Mathisen G. E., Finegold S. M. Branhamella catarrhalis pneumonia. West J Med. 1983 Jan;138(1):47–49. [PMC free article] [PubMed] [Google Scholar]
  10. Luman I., Wilson R. W., Wallace R. J., Jr, Nash D. R. Disk diffusion susceptibility of Branhamella catarrhalis and relationship of beta-lactam zone size to beta-lactamase production. Antimicrob Agents Chemother. 1986 Nov;30(5):774–776. doi: 10.1128/aac.30.5.774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ninane G., Joly J., Kraytman M., Piot P. Bronchopulmonary infection due to beta-lactamase-producing Branhamella catarrhalis treated with amoxycillin/clavulanic-acid. Lancet. 1978 Jul 29;2(8083):257–257. doi: 10.1016/s0140-6736(78)91763-4. [DOI] [PubMed] [Google Scholar]
  12. O'Callaghan C. H., Morris A., Kirby S. M., Shingler A. H. Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother. 1972 Apr;1(4):283–288. doi: 10.1128/aac.1.4.283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Slevin N. J., Aitken J., Thornley P. E. Clinical and microbiological features of Branhamella catarrhalis bronchopulmonary infections. Lancet. 1984 Apr 7;1(8380):782–783. doi: 10.1016/s0140-6736(84)91288-1. [DOI] [PubMed] [Google Scholar]
  14. Stobberingh E. E., van Eck H. J., Houben A. W., van Boven C. P. Analysis of the relationship between ampicillin resistance and beta-lactamase production in Branhamella catarrhalis. Drugs. 1986;31 (Suppl 3):23–27. doi: 10.2165/00003495-198600313-00007. [DOI] [PubMed] [Google Scholar]
  15. Sweeney K. G., Verghese A., Needham C. A. In vitro susceptibilities of isolates from patients with Branhamella catarrhalis pneumonia compared with those of colonizing strains. Antimicrob Agents Chemother. 1985 Apr;27(4):499–502. doi: 10.1128/aac.27.4.499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Wilhelmsen L., Berglund G., Elmfeldt D., Samuelsson O., Svardsudd K. The Multifactor Primary Prevention Trial in Göteborg, Sweden. Comparison with a previously untreated population sample. Drugs. 1986;31 (Suppl 1):47–51. doi: 10.2165/00003495-198600311-00009. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES